Roche Holding AG (OTCMKTS:RHHBY) Given Consensus Rating of “Hold” by Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has earned a consensus rating of “Hold” from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $57.00.

Several analysts recently weighed in on the company. The Goldman Sachs Group raised Roche from a “sell” rating to a “hold” rating in a research note on Thursday, January 15th. HSBC restated a “buy” rating and issued a $57.00 price target on shares of Roche in a research note on Wednesday, December 10th. Barclays upgraded shares of Roche from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a “sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Zacks Research upgraded shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, January 5th.

Roche Trading Up 0.9%

Shares of RHHBY stock opened at $59.55 on Monday. Roche has a fifty-two week low of $34.75 and a fifty-two week high of $60.85. The stock’s fifty day moving average price is $55.49 and its two-hundred day moving average price is $48.10. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72.

Institutional Trading of Roche

A number of hedge funds have recently made changes to their positions in RHHBY. Curio Wealth LLC bought a new stake in shares of Roche during the third quarter worth about $25,000. Oakworth Capital Inc. acquired a new stake in Roche during the 3rd quarter worth approximately $57,000. First Horizon Advisors Inc. grew its holdings in Roche by 81.2% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock worth $75,000 after acquiring an additional 826 shares during the last quarter. Salomon & Ludwin LLC increased its position in Roche by 256.6% in the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after acquiring an additional 2,053 shares during the period. Finally, Atlas Capital Advisors Inc. bought a new position in shares of Roche during the fourth quarter valued at $192,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.